

Title: Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab

PII: S1081-1206(18)30144-3
 DOI: <https://doi.org/10.1016/j.anai.2018.02.017>
 Reference: ANAI 2472



Volume 115 Number 1 February 2015
annals.org

College
of Allergy
and Immunology

Annals of Allergy, Asthma & Immunology

ISSN 0895-8917 THE INTERNATIONAL JOURNAL OF ALLERGY AND IMMUNOLOGY

- Relationship between parental asthma and risk of asthma in children
- Molecular evidence for asthma pathogenesis: phenotypes
- Correlates of the "environmental" "seed" of asthma
- Health and "biological" risk: why does asthma persist in the "environmentally" protected?
- Early life and the developing respiratory tract: why is respiratory health at birth important?



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Treatment of Hypereosinophilic Syndrome and Eosinophilic Dermatitis with Reslizumab

Author:

Merin Kuruvilla, MD

Assistant Professor – Allergy/Immunology

Emory University

Corresponding Author Contact Information:

Merin Elizabeth Kuruvilla, MD

Address: 1365 Clifton Rd NE, Bldg A, 3rd Flr

Atlanta, GA-30322

Email: merin.ek1@gmail.com

Phone: 972-890-3847

Financial support: None

Trial registration: Not applicable

Conflict(s) of Interest: None

Abstract:

Hypereosinophilic syndrome (HES) is a rare disease defined by organ damage directly attributable to hypereosinophilia that is either primary (neoplastic), secondary (reactive) or idiopathic. The mainstay of therapy in idiopathic HES centers around systemic steroids, and cytoreduction with hydroxyurea and interferon-alfa in steroid refractory cases. We describe the successful treatment of recalcitrant, idiopathic cutaneous HES with reslizumab, a humanized interleukin-5 blocker.

Key words:

Idiopathic hypereosinophilic syndrome, Eosinophilia, Eosinophilic dermatitis, Interleukin-5 (IL-5), Reslizumab

Download English Version:

<https://daneshyari.com/en/article/8711690>

Download Persian Version:

<https://daneshyari.com/article/8711690>

[Daneshyari.com](https://daneshyari.com)